OSE Immunotherapeutics To Present at ‘Immuno-Oncology Summit Europe’ and at ‘Tumor Myeloid-Directed Therapies Summit’ in London and Boston
Presentations to focus on CLEC-1, novel myeloid immune checkpoint target for cancer immunotherapy
11/05/2022
T-cell activation through neo-epitopes Transforming tumor microenvironment suppressive cells into effector cells
Down regulating T effector cells to decrease immunological reactivity Up regulating regulatory T-cells to develop immune tolerance
Therapeutic vaccine Prophylactic vaccine Based on T-cells
Premier international pharma, clinical and academic collaborations to speed up the delivery of our product candidates to patients in need
To download the documents
You confirm that you have read our privacy policy. You can unsubscribe at any time by using the unsubscribe links.